| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2142128 | Lung Cancer | 2011 | 5 Pages |
Abstract
Low XOR expression was associated with shortened survival and also conferred a worse prognosis for patients with NSCLC who received adjuvant chemotherapy. Further studies of the XOR pathway are warranted to validate and mechanistically explain these outcomes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anthony W. Kim, Marta Batus, Ronald Myint, Mary J. Fidler, Sanjib Basu, Philip Bonomi, L. Penfield Faber, Sean C. Wightman, William H. Warren, Maria McIntire, Leonidas D. Arvanitis, Paolo Gattuso, Xiulong Xu, Michael J. Liptay,